文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.

作者信息

Camacho-Ortiz Adrián, Gutiérrez-Delgado Eva María, Garcia-Mazcorro Jose F, Mendoza-Olazarán Soraya, Martínez-Meléndez Adrián, Palau-Davila Laura, Baines Simon D, Maldonado-Garza Héctor, Garza-González Elvira

机构信息

Coordinación de Epidemiología Hospitalaria, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.

Servicio de Infectología, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico.

出版信息

PLoS One. 2017 Dec 20;12(12):e0189768. doi: 10.1371/journal.pone.0189768. eCollection 2017.


DOI:10.1371/journal.pone.0189768
PMID:29261736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5738078/
Abstract

OBJECTIVE: The aim of this study was to evaluate the impact of fecal donor-unrelated donor mix (FMT-FURM) transplantation as first-line therapy for C. difficile infection (CDI) in intestinal microbiome. METHODS: We designed an open, two-arm pilot study with oral vancomycin (250mg every 6 h for 10-14 days) or FMT-FURM as treatments for the first CDI episode in hospitalized adult patients in Hospital Universitario "Dr. Jose Eleuterio Gonzalez". Patients were randomized by a closed envelope method in a 1: 1 ratio to either oral vancomycin or FMT-FURM. CDI resolution was considered when there was a reduction on the Bristol scale of at least 2 points, a reduction of at least 50% in the number of bowel movements, absence of fever, and resolution of abdominal pain (at least two criteria). From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Specimens were cultured to isolate C. difficile, and isolates were characterized by PCR. Susceptibility testing of isolates was performed using the agar dilution method. Fecal samples and FMT-FURM were analyzed by 16S rRNA sequencing. RESULTS: We included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. However, one of the patients in the vancomycin arm and two patients in the FMT-FURM arm were eliminated. Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, while symptoms resolved in 4/7 patients (57.1%) after the first FMT-FURM dose (P = 0.26) and in 5/7 patients (71.4%) after the second dose (P = 0.55). During the study, no adverse effects attributable to FMT-FURM were observed in patients. Twelve isolates were recovered, most isolates carried tcdB, tcdA, cdtA, and cdtB, with an 18-bp deletion in tcdC. All isolates were resistant to ciprofloxacin and moxifloxacin but susceptible to metronidazole, linezolid, fidaxomicin, and tetracycline. In the FMT-FURM group, the bacterial composition was dominated by Firmicutes, Bacteroidetes, and Proteobacteria at all-time points and the microbiota were remarkably stable over time. The vancomycin group showed a very different pattern of the microbial composition when comparing to the FMT-FURM group over time. CONCLUSION: The results of this preliminary study showed that FMT-FURM for initial CDI is associated with specific bacterial communities that do not resemble the donors' sample.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ca01cbee6696/pone.0189768.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/338d7fa7a64d/pone.0189768.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ac66cd3b3b02/pone.0189768.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/62c000f88df7/pone.0189768.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ca909a8a4c61/pone.0189768.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/d426525f7339/pone.0189768.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/9e38697f37e4/pone.0189768.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ca01cbee6696/pone.0189768.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/338d7fa7a64d/pone.0189768.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ac66cd3b3b02/pone.0189768.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/62c000f88df7/pone.0189768.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ca909a8a4c61/pone.0189768.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/d426525f7339/pone.0189768.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/9e38697f37e4/pone.0189768.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb2/5738078/ca01cbee6696/pone.0189768.g007.jpg

相似文献

[1]
Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.

PLoS One. 2017-12-20

[2]
Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.

PLoS One. 2018-1-31

[3]
Intestinal Microbiome Changes in Fecal Microbiota Transplant (FMT) FMT Enriched with in the Treatment of Recurrent Infection.

Can J Gastroenterol Hepatol. 2019-12-28

[4]
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.

Transpl Infect Dis. 2016-8

[5]
Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota.

Gut Microbes. 2017-5-4

[6]
Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.

mBio. 2016-12-20

[7]
Effect of Aging on the Composition of Fecal Microbiota in Donors for FMT and Its Impact on Clinical Outcomes.

Dig Dis Sci. 2017-4

[8]
The success of fecal microbial transplantation in infection correlates with bacteriophage relative abundance in the donor: a retrospective cohort study.

Gut Microbes. 2019-3-13

[9]
Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach.

Gut Microbes. 2017-5-4

[10]
Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in the Elderly: Long-Term Outcomes and Microbiota Changes.

Dig Dis Sci. 2016-10

引用本文的文献

[1]
Comparative effectiveness of different therapies for infection in adults: a systematic review and network meta-analysis of randomized controlled trials.

Lancet Reg Health Eur. 2025-1-5

[2]
Protective effects of fecal microbiota transplantation against ischemic stroke and other neurological disorders: an update.

Front Immunol. 2024

[3]
Clostridioides Difficile in Latin America: An Epidemiological Overview.

Curr Microbiol. 2023-9-28

[4]
Research trends on clinical fecal microbiota transplantation: A biliometric analysis from 2001 to 2021.

Front Immunol. 2022

[5]
The interplay of gut microbiota between donors and recipients determines the efficacy of fecal microbiota transplantation.

Gut Microbes. 2022

[6]
Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis.

Ann Gastroenterol. 2022

[7]
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.

J Neurogastroenterol Motil. 2022-1-30

[8]
Fecal microbiota transplants: A review of emerging clinical data on applications, efficacy, and risks (2015-2020).

Qatar Med J. 2021-2-22

[9]
South African Society of Clinical Microbiology infection diagnosis, management and infection prevention and control guideline.

S Afr J Infect Dis. 2020-10-28

[10]
Feature selection and causal analysis for microbiome studies in the presence of confounding using standardization.

BMC Bioinformatics. 2021-7-6

本文引用的文献

[1]
Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.

Aliment Pharmacol Ther. 2017-9

[2]
Burden of Clostridium difficile infection in the United States.

N Engl J Med. 2015-6-11

[3]
Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection.

Aliment Pharmacol Ther. 2015-5

[4]
Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.

BMC Infect Dis. 2014-11-26

[5]
Subsampled open-reference clustering creates consistent, comprehensive OTU definitions and scales to billions of sequences.

PeerJ. 2014-8-21

[6]
Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Expert Rev Anti Infect Ther. 2014-1

[7]
Advancing our understanding of the human microbiome using QIIME.

Methods Enzymol. 2013

[8]
Duodenal infusion of donor feces for recurrent Clostridium difficile.

N Engl J Med. 2013-1-16

[9]
Human gut microbiome viewed across age and geography.

Nature. 2012-5-9

[10]
Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.

Am J Gastroenterol. 2012-3-27

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索